The role of dietary factors in the prevention and management of inflammatory bowel disease: a comprehensive review Authors: Elyas Nattagh-Eshtivani, Hanieh Barghchi, Amir Hossein Mansouri, Pegah Rahbarinejad, Amin Mokari-Yamchi, Mehdi Barati, Mohammad Rashidmyvan, Ali Jafazadeh Esfehani, Alireza Mohammadzadeh, Zachry Clyton, Parisa Marabi, Saeedeh Talebi, Naseh Pahlavani Published: 2025 ABSTRACT Crohn’s disease (CD) and ulcerative colitis (UC), the two main forms of inflammatory bowel disease (IBD), are chronic conditions characterized by relapsing inflammation in the gastrointestinal tract. Although the etiology of IBD remains unclear, it is now well-established that both genetic susceptibility and environmental factors including diet, play essential roles in its pathogenesis. Dietary components can influence gut microbiota composition, immune regulation, and intestinal barrier integrity, thereby modulating disease onset, severity, and relapse. While some nutritional patterns and specific nutrients show therapeutic potential, others may aggravate inflammation. This comprehensive review explores the influence of macronutrients, micronutrients, and dietary regimens such as the Mediterranean diet, low FODMAP, and exclusive enteral nutrition on IBD. Additionally, the review highlights current evidence, clinical relevance, and research gaps in using dietary strategies to prevent and manage IBD effectively. Introduction Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), represents a chronic, relapsing inflammation of the gastrointestinal (GI) tract. CD can affect any segment of the GI tract with transmural involvement, while UC is limited to the colon and rectum with superficial mucosal inflammation [1]. Globally, IBD incidence has risen markedly, with > 3 million cases in the United States alone [2]. Similar increases in developing regions are linked to dietary westernization [3]. Symptoms range from abdominal cramps and mild diarrhea to severe pain, gastrointestinal bleeding, fistulae, and weight loss [3, 4]. Although its precise etiology is unknown, environmental factors such as smoking, oral contraceptives, appendectomy, childhood infections, and low-quality diets are strongly associated with altered gut microbiota and heightened IBD risk [3, 5]. Drug treatments are considered the first-line therapy for IBD, including corticosteroids, cyclosporine, azathioprine/6-mercaptopurine, anti-tumor necrosis factor therapy, and aminosalicylates [5, 6]. However, other therapeutic options are emerging including apheresis therapy, improved intestinal micro ecology, exosome therapy, involving small molecules, and cell therapy [7]. In addition to pharmacological treatments, complementary and alternative therapies have also become common for the control and treatment of CD and UC [8]. Based on previous studies, diet can play an important role in different stages of IBD progression, including prevention, treatment, and rehabilitation [9, 10]. Adherence to a western diet, characterized by high consumption of refined sugars, animal protein, fat, and processed meats, and reduced intake of soluble fiber, may trigger pro-inflammatory processes that ultimately lead to IBD development [11]. Changes in the intake of certain macro- and micronutrients can affect the risk of IBD; for example, increased intake of omega-6 fatty acids along with reduced intake of omega-3 fatty acids has been implicated as a contributing factor [12]. A systematic review and meta-analysis reported that increasing long-chain omega-3 fatty acid intake is associated with reduced risk of IBD recurrence and lower erythrocyte sedimentation rate (ESR), while data on omega-6 fatty acids remain insufficient, though they are likely to have minimal effects on IBD [13]. More than half of individuals with IBD believe that certain foods trigger disease relapse, and about 60% follow an elimination diet during their illness [14]. In general, consumption of specific dietary components, such as antioxidants, vitamin D, plant proteins, and probiotics, has been associated with reduced incidence of IBD [9, 10]. However, the exact mechanisms by which these dietary constituents influence IBD pathogenesis remain unclear. The purpose of this review is to comprehensively examine the role of nutritional and dietary factors including macronutrients (specifically carbohydrates, fats, protein, and fiber), various therapeutic diets (such as the low FODMAP, Mediterranean, Anti-inflammatory, Exclusive Enteral Nutrition, and Immunoglobulin Exclusion diets), and key dietary supplements (including vitamin B12, vitamin D, calcium, iron, zinc, antioxidants, and probiotics) in the pathophysiology of IBD. Macronutrients Carbohydrates Carbohydrate intake may affect IBD risk through gut microbiota modulation and immune pathways [15, 16]. High sugar consumption, typical of Western diets, promotes dysbiosis, TNF-α release, and impaired barrier function [17]. In animal models, excessive sugar worsened colitis by depleting short-chain fatty acids (SCFAs) [18–20]. Observational human studies show conflicting results. Some report higher intake of total carbohydrates, starch, and refined sugar in UC and CD patients [21], including associations with high sucrose consumption [22] and bread intake [23, 24]. However, large cohort studies and meta-analyses have not consistently confirmed these associations. For example, the European prospective investigation into cancer and nutrition study and other reviews found no significant link between total carbohydrate, sugar, or starch intake and IBD risk [25, 26]. A meta-analysis of nine studies did note a possible link between sucrose and UC, but no consistent association with total carbohydrate intake [27]. Although low refined carbohydrate intake did not reduce CD relapse in one controlled trial, it was associated with improved clinical remission [28]. Overall, evidence remains inconclusive, and further well-controlled studies are needed to clarify the role of different carbohydrate types in IBD onset and progression. Fiber Dietary fiber has well-established benefits for gut homeostasis, reducing inflammation, modulating immune responses, and supporting a healthy microbiota in IBD [29]. Mechanistically, fiber modifies gut pH and permeability, which can diminish inflammation [30]. For example, CD patients receiving 15 g/day of fructo-oligosaccharides for 4 weeks showed reduced interleukin-6 (IL-6)-positive dendritic cells and increased anti-inflammatory IL-10 expression without affecting IL-12p40 production [31]. Similarly, UC patients supplemented with germinated barley (30 g/day for 2 months) exhibited decreased serum C-reactive protein (CRP), a marker of systemic inflammation [32]. Ferulic acid, a phenolic antioxidant found in cereals, also displays potential anti-inflammatory properties in the digestive tract [33]. Fiber supports gut microbiota by providing substrates for fermentation, generating SCFAs such as butyrate and propionate, which enhance mucosal immunity and serve as energy sources [34–36]. For instance, UC patients consuming a low-fat, high-fiber diet for four weeks showed increased fecal abundance of Bacteroidetes, Faecalibacterium prausnitzii, and higher levels of acetate SCFA [37]. Modern Western diets supply far less fiber than traditional diets, and both healthy individuals and IBD patients often fail to meet recommended intake levels, with most studies showing lower consumption among IBD patients [38–41]. though most studies find lower fiber intake among IBD patients [41]. Observational evidence indicates that plant-based and high-fiber dietary patterns may reduce inflammation and are associated with decreased CD risk, though this association is not consistently observed for UC [42, 43]. Beyond metabolic effects, fiber may directly modulate intestinal immune pathways. Experimental models show that specific fiber components, such as apple-pectin–derived oligogalactan, can attenuate TLR-mediated inflammatory responses, providing additional mechanistic support for fiber’s anti-inflammatory and potentially anti-carcinogenic roles [44, 45]. Fat Dietary fat has been extensively studied in relation to IBD, but findings remain inconsistent. Experimental models show that high-fat diets can disrupt gut microbiota, alter gene expression, and promote immune cell infiltration in the colon [46]. Population studies report mixed results. Some found no association between total fat, saturated fat, or mono- and polyunsaturated fat intake and IBD risk after adjusting for energy intake. However, long-chain n-3 PUFAs appear to be protective against UC [46], while high trans-fat intake may increase risk [47]. Others report lower CD risk with higher n-3/n-6 fatty acid ratios [48], or an increased UC risk with high PUFA consumption [25, 49]. Systematic reviews remain inconclusive. One showed an association between higher intake of saturated fats, omega-6, and total PUFAs with CD, and between total fat, omega-6, and PUFAs with UC [50]. Mechanistically, high-fat diets may increase colonic inflammation via altered lipid metabolism and microbial byproducts such as secondary bile acids or hydrogen sulfide [51] (Fig. 1). Fig. 1Normal condition. Probiotics aid in homeostasis maintenance in a number of ways, including: preventing pathogenic bacteria from having an effect by producing antibacterial substances and competing with pathogens for binding to epithelial cells; promoting intestinal epithelial cell homeostasis by enhancing barrier function, mucus production, survival, and cytoprotective responses; defining the balance between adequate and excessive defense immunity by boosting innate immunity (including the production of IgA and defensin. Inflammatory condition. Western diets with a lot of sugar lead to dysbiosis of the gut flora. The colonization of the gut by adherent, invasive Escherichia coli and subsequent microbiota promotes intestinal inflammation via the production of the proinflammatory cytokine tumor necrosis factor alpha. A high-fat diet enhanced colonic local inflammation. Zn insufficiency among IBD sufferers Increase intestinal inflammation via activating dendritic cells. Antioxidants like resveratrol, quercetin, curcumin, lower the production of reactive oxygen species and reduce the production of proinflammatory cytokines including TNF-a, IL-8, and IL-6 in macrophages and neutrophils. DC; dendritic cell, ROS; reactive oxygen species, Zn2+; Zinc 2+, IDO; indoleamine 2,3-dioxygenase (IDO), BAFF; B-cell activating factor, APRIL; A proliferation-inducing ligand, MCP; Monocyte chemoattractant protein, TNF-a; Tumor necrosis factor alpha, IgA; Immunoglobulin A, IgG; Immunoglobulin G, IL-21; Interleukin-21, IL-17; Interleukin-17, IL-10; Interleukin-21, IL-8; Interleukin-8, IL-22; Interleukin-22, TGF-β; Transforming growth factor beta This figure was created by the authors (designed by Dr. Barati) Normal condition. Probiotics aid in homeostasis maintenance in a number of ways, including: preventing pathogenic bacteria from having an effect by producing antibacterial substances and competing with pathogens for binding to epithelial cells; promoting intestinal epithelial cell homeostasis by enhancing barrier function, mucus production, survival, and cytoprotective responses; defining the balance between adequate and excessive defense immunity by boosting innate immunity (including the production of IgA and defensin. Inflammatory condition. Western diets with a lot of sugar lead to dysbiosis of the gut flora. The colonization of the gut by adherent, invasive Escherichia coli and subsequent microbiota promotes intestinal inflammation via the production of the proinflammatory cytokine tumor necrosis factor alpha. A high-fat diet enhanced colonic local inflammation. Zn insufficiency among IBD sufferers Increase intestinal inflammation via activating dendritic cells. Antioxidants like resveratrol, quercetin, curcumin, lower the production of reactive oxygen species and reduce the production of proinflammatory cytokines including TNF-a, IL-8, and IL-6 in macrophages and neutrophils. DC; dendritic cell, ROS; reactive oxygen species, Zn2+; Zinc 2+, IDO; indoleamine 2,3-dioxygenase (IDO), BAFF; B-cell activating factor, APRIL; A proliferation-inducing ligand, MCP; Monocyte chemoattractant protein, TNF-a; Tumor necrosis factor alpha, IgA; Immunoglobulin A, IgG; Immunoglobulin G, IL-21; Interleukin-21, IL-17; Interleukin-17, IL-10; Interleukin-21, IL-8; Interleukin-8, IL-22; Interleukin-22, TGF-β; Transforming growth factor beta This figure was created by the authors (designed by Dr. Barati) Overall, although some fat subtypes show risk modification potential, evidence is heterogeneous. A diet lower in refined fats and processed foods may benefit IBD patients [26]. More rigorous studies are needed for firm conclusions. Protein High total protein intake particularly from animal sources has been associated with increased IBD risk in several studies [52]. Red and processed meats may contribute to inflammation via compounds such as hydrogen sulfide, heme iron, and cooking-derived carcinogens [53, 54] (Fig. 1). However, associations are inconsistent: while some cohorts report links between processed meat and UC, other protein sources show no clear correlation [55]. On the other hand, specific amino acids and protein sources may modulate inflammation. These effects depend on digestion, absorption, gut microbiota interaction, and residue reaching the colon [56]. In meta-analyses, dietary protein showed no consistent association with UC or CD risk overall [53]. However, one study found increased IBD risk in Asian but not western populations with high protein intake, possibly reflecting broader dietary patterns rather than protein’s independent effects [57]. These discrepancies suggest that protein’s role may depend more on source, processing, and broader dietary context than on total intake alone. Further research is needed to clarify whether specific amino acids or protein-derived metabolites meaningfully influence IBD pathogenesis. Diets Low FODMAP diet Fermentable oligosaccharides, disaccharides, monosaccharides, and polyol (FODMAP) are short-chain carbohydrates with low intestinal absorption and high osmotic activity, including lactose, fructose, fructooligosaccharides (FOS), galacto-oligosaccharides (GOS), xylitol, lactitol, and isomalt [58]. The low FODMAP diet is recommended during remission for IBD patients experiencing functional gastrointestinal symptoms (FGS) such as bloating, diarrhea, and abdominal pain [59]. Further, carbohydrate malabsorption like lactose, fructose, maltose, and saccharose is more prevalent in patients with IBD than in other healthy individuals [60] (Fig. 1), and reducing fermentable carbohydrates may decrease symptoms by limiting bacterial fermentation and osmotic effects [61]. Clinical studies indicate that a low FODMAP diet can improve quality of life and may reduce symptom burden or support remission in CD (P < 0.01) [62, 63]. However, it does not consistently improve symptoms such as nausea, or vomiting (RR: 0.54, 95% CI: 0.22–1.32, p = 0.18) [61], nor does it significantly reduce intestinal inflammation (67). Moreover, its restrictive nature often leads to reduced fiber intake, raising concerns about malnutrition and negative impacts on gut microbiota composition [58, 64]. Given these limitations, diet should be applied short-term and under dietitian supervision, with structured reintroduction phases to prevent nutrient deficiencies. Although originally designed for IBS, it may help manage IBS-like symptoms, which occur in over 40% of IBD patients [65]. Lactose-intolerant patients should incorporate lactose-free alternatives to maintain nutrition. In summary, while helpful for managing functional symptoms in IBD remission, the low FODMAP diet is not effective against inflammation and may be harmful if followed long-term without proper nutritional management. Mediterranean diet (MD) The Mediterranean diet (MD), characterized by high intake of plant-based foods and olive oil with moderate fish and limited meat and sweets, supports gut health by promoting beneficial microbiota and reducing intestinal inflammation [66, 67]. This dietary pattern promotes gut health primarily by enhancing beneficial gut bacteria, which maintain intestinal barrier function and reduce inflammation [68]. For instance, the MD has been shown to increase populations of Akkermansia, Adlercreutzia, and Ruminococcaceae, while reducing pro-inflammatory bacteria such as Fusobacterium and Proteobacteria. Clinical data indicate that higher MD adherence is linked with improved quality of life, healthier microbial profiles, lower fecal calprotectin, and reduced disease progression in IBD, with some studies suggesting a role in CD remission [69–71]. In UC, adherence is inversely associated with relapse risk (r = 0.2; p = 0.040) [70]. Additionally, in IBD patients with hepatic steatosis, the MD has been shown to lessen NAFLD severity (p < 0.05) [72]. Given its anti-inflammatory and microbiota-modulating properties, the MD is considered a beneficial dietary strategy to support disease control and reduce progression in both CD and UC, with nutritional education. Anti-inflammatory diet (AID) The Anti-inflammatory Diet for IBD (IBD-AID) is characterized by restricting refined carbohydrates and lactose, increasing consumption of prebiotics (such as soluble fiber, leeks, and onions) and probiotics (such as yogurt, kefir, and fermented foods), prioritizing omega-3-rich foods, and reducing total and saturated fat intake (Fig. 1) [73]. Probiotics and prebiotics show promise as microbiota-targeted interventions in IBD. In UC, E. coli Nissle, VSL#3, and Lactobacillus rhamnosus GG improved remission and clinical outcomes, while fermented milk and yogurt containing Bifidobacterium and Lactobacillus reduced relapse and modulated immunity. Lactobacillus GG was ineffective in CD. Prebiotics selectively promote beneficial gut bacteria; in UC, oat bran increased fecal butyrate and improved gastrointestinal symptoms, and germinated barley foodstuff (GBF) reduced clinical activity, CRP, and relapse rates, while wheat bran improved clinical scores in CD. Overall, both probiotics and prebiotics are safe, generally more effective in UC, and show potential as adjunct therapies, though larger studies are needed to confirm long-term benefits. The diet is typically introduced in phases based on disease activity, starting with soft, pureed, seed-free foods post-flare, followed by well-cooked vegetables, peeled fruits, lean meats, and a gradual reintroduction of more varieties as tolerated [73]. Limited but promising evidence suggests that AID may help maintain remission and reduce disease flares in IBD. In case series and small studies, adherence to the diet has been associated with decreased bowel frequency, improved disease severity, and in some cases, reduced dependence on IBD medications [74, 75]. A pilot study also reported that higher intake of fiber-rich foods, probiotics, lean protein, and omega-3 promoted the growth of anti-inflammatory gut bacteria (such as Clostridia and Bacteroides), along with reductions in inflammatory cytokines (IL-6, IL-8 and TNF-α) (Fig. 1) [76]. Epigenetic and microbiome analyses in UC patients indicate that an anti-inflammatory diet can beneficially modulate gut microbiota composition and gene expression [77]. Despite these positive findings, current data are based on small or non-randomized studies. Well-designed prospective clinical trials are required to validate the efficacy and safety of the AID in IBD management. Exclusive enteral nutrition (EEN) Enteral nutrition strategies for IBD include exclusive enteral nutrition (EEN), partial enteral nutrition (PEN), and the CD exclusion diet (CDED). EEN consists of elemental, semi-elemental, or defined formula diets and is the exclusive source of nutrition; PEN combines formula with regular food (typically 50:50); and CDED allows specific foods (such as chicken, potato, apple, banana, and eggs) while excluding additives, dairy, gluten, and limiting red meat, promoting fiber, fruits, and vegetables [78, 79]. EEN, using formula as the sole nutrient source, is an established induction therapy for pediatric CD and achieves mucosal healing comparable or superior to corticosteroids [80, 81]. Its benefits likely result from reduced exposure to pro-inflammatory dietary components, immunomodulatory effects of formulas, and favorable microbiota shifts such as increases in Ruminococcus species (p = 0.049) [82]. EEN may also reduce inflammatory markers (CRP and faecal calprotectin levels (both P = 0.04) in acute severe UC, though adherence remains challenging, especially in adults [83, 84]. More flexible approaches such as CDED combined with PEN show similar remission induction and maintenance rates to EEN in children with mild-to-moderate CD, with better patient acceptability [69, 85, 86]. Symptom improvement has also been observed in some patients unresponsive to biologics [87, 88]. Dietary interventions may also impact IBD-related metabolites, such as kynurenine, ceramides, succinate, and N-α-acetyl-arginine [89]. The CD_TREAT diet, designed to replicate EEN effects using ordinary foods with key exclusions, has demonstrated microbiome changes similar to EEN in short-term human and animal studies, though additional clinical validation is needed [90, 91]. In summary, exclusive dietary therapies, including EEN, PEN, and CDED, are effective options for inducing remission, particularly in pediatric with CD. However, greater adherence and long-term efficacy require additional research through clinical trials to identify optimal dietary strategies. Immunoglobulin exclusion diet (IED) The Immunoglobulin Exclusion Diet (IED) involves eliminating foods that elicit elevated food-specific IgG antibodies, particularly IgG4, which are more prevalent in CD than in patients with UC [92]. Common excluded foods include eggs, cow’s milk and dairy products, beef, pork, and wheat [93]. Clinical studies indicate that IgG4-guided exclusion diets can improve disease activity and quality of life. For instance, Gunasekeera et al. demonstrated symptom improvement in CD patients after excluding high IgG4-reactive foods. Rajendran et al. reported reductions in the CD activity index (CDAI) and inflammatory markers such as erythrocyte sedimentation rate (ESR) following IED [94, 95]. Similarly, a six-month intervention in patients with UC, improved nutritional status (P < 0.05), quality of life (P < 0.01), and disease activity (P < 0.05) compared to a standard diet [96]. IED may also support maintenance of remission post-EEN by significantly lowering IgG4 titers [92, 95]. The proposed mechanism involves reduction of IgG-antigen immune complexes, which otherwise activate intestinal mast cells and exacerbate inflammation. By eliminating IgG4-reactive foods, this pathway may be attenuated, potentially alleviating symptoms in IBD and related disorders such as IBS. Despite these promising findings, data on IED’s effects on intestinal microbiota and long-term nutritional adequacy are limited. Well-designed clinical trials are necessary to establish efficacy, safety, and underlying mechanisms. Dietary supplements Vitamin B12 Vitamin B12 (cobalamin) is essential for nucleic acid synthesis and erythropoiesis. Deficiency can cause macrocytic anemia and neurological dysfunction. Anemia is a common complication in IBD, particularly among CD patients, with prevalence rates reported between 12% and 43% [97, 98]. Given that the terminal ileum is the main site of B12 absorption, resections longer than 20–30 cm in CD patients significantly increase the risk of deficiency and justify supplementation [99, 100]. A meta-analyses indicate no significant difference in serum B12 levels between IBD patients overall and healthy controls, though some ethnic variations exist; for example, lower serum B12 has been reported in Asian IBD population [101, 102]. Diagnosis relies on serum cobalamin measurement (< 148 pmol/L suggests deficiency), but levels alone may be insufficient, especially in asymptomatic cases, requiring additional biomarkers such as methylmalonic acid [103]. Treatment guidelines, such as those from the British Committee for Standards in Haematology and the American Society of Hematology, recommend 1000 mcg of intramuscular B12 every other day for one week, followed by weekly injections until clinical improvement, then monthly maintenance doses for life, especially in cases with malabsorption or surgery. For megaloblastic anemia, supplementation continues for up to 8 weeks [99]. Overall, vitamin B12 supplementation is particularly important in CD patients with ileal involvement or surgery, but wider screening and confirmatory testing are essential to avoid unnecessary treatment in asymptomatic individuals. Vitamin D and calcium Vitamin D, a fat-soluble vitamin, is essential for maintaining gastrointestinal epithelial barrier integrity, regulating gut microbiota and immune responses, and enhancing calcium absorption critical for musculoskeletal health [104–106]. These functions play an important role in IBD prevention and symptom management [104]. Vitamin D deficiency is more prevalent in IBD patients than in the general population, particularly in CD compared to UC, and may influence disease etiology and severity [104, 107]. The normalization of serum 25-hydroxyvitamin D (25-OH-D) offers multiple benefits in IBD, including reduced CD surgery risk (OR, 1.76; 95% CI, 1.24–2.51) [108], decreases in inflammatory markers [109], lowered anemia incidence [110], improved response to anti-TNF-α therapy [111], decreased colorectal cancer risk [112] and reduced upper respiratory infections [113]. A recent meta-analysis of 17 randomized controlled trials confirmed the safety and tolerability of oral vitamin D supplementation and its effectiveness in lowering CRP [standard mean difference (SMD) -0.33; 95% CI -0.61, -0.05], though it did not significantly affect ESR (SMD 0.35; 95% CI -4.33, 5.03), disease activity (SMD − 0.13; 95% CI -0.66, 0.39), and relapse rates (RR 0.59; 95% CI 0.19, 1.86) [114]. Cholecalciferol is preferred over ergocalciferol due to superior serum 25-OH-D elevation [115]. The European food safety authority sets the upper daily limit at 4000 IU, while recent reviews suggest doses between 1800 and 10,000 IU for IBD patients [116–118] . IBD is associated with impaired bone metabolism, including osteopenia and osteoporosis, influenced by inflammation, corticosteroid use, age, malnutrition, and deficiencies in calcium and vitamin D [119, 120]. Corticosteroids negatively impact bone by impairing osteoblasts, reducing intestinal calcium absorption, and increasing renal calcium excretion [121, 122]. Therefore, calcium and vitamin D supplementation is recommended for IBD patients receiving corticosteroids. IBD patients often have lower dietary calcium intake than healthy controls, partly due to beliefs that dairy products exacerbate symptoms, and clinical advice to limit dairy in cases of diarrhea [123, 124]. However, lactose-low dairy products like cheese and yogurt provide important calcium with less intolerance risk and may reduce gut inflammation by promoting butyrate-producing bacteria and modulating immune responses [125, 126]. Specifically, vitamin D-fortified dairy has shown efficacy in preventing bone loss in CD [127]. Hence, dairy consumption should not be neglected in IBD management. Iron Iron deficiency anemia (IDA) is a common extraintestinal complication in IBD that significantly reduces quality of life and increases morbidity and mortality. Symptoms include chronic fatigue, lethargy, headache, angina, abdominal pain, dyspnea, mental disorders, and higher hospitalization risk [128–130]. Normally, healthy individuals absorb 1–2 mg of iron daily from dietary heme and non-heme sources, however, many IBD patients experience food intolerance leading to inadequate iron intake [131]. Malabsorption due to duodenal involvement or surgery, as well as chronic blood loss from mucosal ulcerations, also contributes to iron deficiency [132, 133]. Additionally, medications like methotrexate and systemic inflammation impair iron metabolism and erythropoiesis [129, 132]. More than one-third of IBD patients suffer from recurrent anemia, yet studies show that less than half receive appropriate anemia treatment [132, 134–136]. Regular monitoring of hemoglobin, mean corpuscular volume (MCV), serum ferritin, and inflammatory markers such as CRP is essential for early detection and treatment guidance [137]. Treatment options include oral and intravenous (IV) iron supplementation, along with erythropoiesis-stimulating agents. While IV iron is associated with fewer gastrointestinal side effects and faster anemia correction [138–141], oral iron remains more accessible and cost-effective with similar impacts on quality of life and disease activity in certain cases [130]. However, oral iron may be less effective in active disease due to malabsorption and inflammation [133]. European crohn’s and colitis organisation (ECCO) guidelines recommend iron supplementation for all IBD patients with IDA. IV iron is preferred when oral intolerance exists, disease activity is high, hemoglobin is below 10 g/dL, or erythropoiesis stimulation is required [137]. Successful therapy aims for a hemoglobin increase of at least 2 g/dL within 4 weeks and normalization of iron stores evidenced by transferrin saturation increase of > 30% or serum ferritin above 10 µg/L [129, 142, 143]. Nutritional interventions including dietitian-guided intake of iron-rich or fortified foods, monitoring anemia parameters, preventing weight loss, and supporting anti-inflammatory diets during remission can improve disease outcomes and patient quality of life. Zinc Zinc (Zn) is an essential micronutrient with anti-inflammatory and antioxidant properties, crucial for epithelial barrier integrity, tissue repair, growth, and immune regulation [144, 145]. IBD patients are prone to zinc deficiency due to impaired intestinal absorption, especially in CD, and increased losses through diarrhea, fistulas, and ostomies [145–147]. Prevalence of zinc reduces intestinal bactericidal capacity via metallothionein-1 regulation deficiency in IBD ranges from 15% to 65% [148, 149]. A meta-analyses indicate no significant difference in dietary zinc intake between UC patients and healthy controls (SMD 0.18 ; 95% CI − 0.22, 0.58) [150], whereas low serum zinc levels are significantly associated with increased risk and prevalence of zinc deficiency in CD [147, 151, 152]. Zinc deficiency exacerbates intestinal inflammation by activating macrophages [153], reduces intestinal bactericidal capacity via metallothionein-1 regulation [154], disrupts epithelial homeostasis [155], and decreases expression of critical tight junction proteins occludin and ZO-1 [156] leading to increased intestinal permeability and higher hospitalization risk [157]. Zinc supplementation improves clinical outcomes, lowers MT1G and ZIP-14 gene expression, normalizes gut permeability, and reduces relapse rates [158, 159]. Effective benefits require at least three months of supplementation [153]. Dietary zinc-rich foods include oysters, pig liver, beef, chicken, flat iron steak, and scallops [160]. However, not all of the listed foods can be consumed by patients with IBD during a flare-up of the disease. They should be guided by a specialized nutritionist. However, dietary intake alone generally fails to correct zinc deficiency in IBD. Supplementation should be personalized, with recommended doses of 50–100 mg/day for adults and 1–3 mg/kg/day for children [153]. Antioxidants Oxidative stress (OS) plays a pivotal role in IBD pathogenesis, originating in the inflamed intestinal mucosa and potentially progressing to deeper intestinal layers and systemic circulation [161–163]. Excessive production of reactive oxygen species (ROS), reactive nitrogen species (RNS), and reactive sulfur species (RSS) contributes to disease progression by affecting gene regulation, mitochondrial function, DNA integrity, and ion transport [164]. The reactive species interactome (RSI) model highlights the role of these species in modulating protein cysteine redox switches, altering cellular signaling [165]. Antioxidants (AOs) including natural compounds, hormones, probiotics, vitamins C and E, and synthetic agents, counteract oxidative damage, modulate immune responses, and improve IBD outcomes via multiple mechanisms, such as free radical scavenging and regulation of pro-oxidative enzymes and cytokines [166–168] (Fig. 1). Clinical studies exploring AOs supplementation in IBD show promising but limited results. For example, combined vitamin C (1000 mg) and E (800 IU) supplementation in CD patients for four weeks decreased OS markers without altering disease activity [167]. N-acetyl-L-cysteine (NAC) demonstrated antioxidative and anti-inflammatory effects in both animal models and humans, reducing colonic inflammation and cytokines (Interleukin-8 (IL-8), Monocyte chemoattractant protein-1 (MCP-1)) when given with mesalamine in UC patients [168, 169]. Fish oil (2.7 g/day Eicosatetraenoic acid (EPA) and Docosahexaenoic acid (DHA)) alongside vitamins A, C, E, and selenium improved inflammatory cytokine profiles in CD over 24 weeks [170]. Natural antioxidants such as pycnogenol improved biomarkers including superoxide dismutase (SOD), calprotectin, CRP, total antioxidant capacity (TAC), and glutathion peroxidase (GPX) in pediatric CD patients after 10 weeks [171, 172]. Silymarin supplementation (140 mg/day) for six months improved ESR, hemoglobin, and disease activity in UC patients [173]. Experimental evidence supports beneficial effects of resveratrol, curcumin, quercetin, catechins, and synthetic antioxidants like melatonin, ACE inhibitors, HMG-CoA reductase inhibitors, modified SOD, and propionyl-L-carnitine in reducing inflammation and oxidative stress [174–198]. In summary, AOs supplementation may benefit patients with mild to moderate IBD by lowering oxidative stress and inflammatory markers and improving clinical symptoms. However, existing trials generally involve low doses and short treatment durations, underscoring the need for larger, well-designed clinical studies to clarify optimal dosing and long-term efficacy. Probiotics Alterations in gut microbiota and abnormal immune responses to commensal gut microbiota have been implicated in the pathogenesis of IBD [199, 200]. Consequently, probiotic supplementation has gained attention as a potential therapeutic option in UC and CD. Probiotics are live microorganisms which, when administered in adequate amounts, confer health benefits by modulating gut microbial balance and have demonstrated efficacy in various gastrointestinal disorders [201, 202]. In UC patients (both adults and children) the non-pathogenic strain Escherichia coli Nissle 1917 has shown similar effectiveness and safety to mesalazine (5-aminosalicylic acid) for induction and maintenance of remission [203, 204]. The probiotic cocktail VSL#3, containing multiple Lactobacillus and Bifidobacterium species plus Streptococcus thermophilus, has been effective in inducing remission in UC patients unresponsive to standard therapy [205]. A systematic review and meta-analysis by Shen et al. confirmed that VSL#3 and E. coli Nissle 1917 are the only probiotics with robust evidence supporting their efficacy in maintaining UC remission, while other probiotics lack proven benefit and are not recommended for IBD patients [206]. Animal colitis models indicate probiotics exert both preventive and therapeutic effects, although mechanisms remain incompletely understood. Benefits depend on probiotic strain, dosage, and disease severity. Probiotics appear to restore gut microbial homeostasis, enhance intestinal epithelial barrier integrity, and modulate local and systemic immune responses [207]. Molecularly, probiotics inhibit the nuclear factor kappa B (NF-κB) pathway, reducing pro-inflammatory cytokine production [208–210], and activate peroxisome proliferator-activated receptor-gamma (PPARγ), which exerts anti-inflammatory effects [211, 212]. Conclusion Diet and nutrition play a fundamental and measurable role in shaping the clinical course of IBD. Across the evidence reviewed, several consistent themes emerge. First, although findings regarding macronutrients such as carbohydrates, fats, and proteins remain heterogeneous, the cumulative data support minimizing ultra-processed foods and emphasizing fiber-rich dietary patterns, which contribute to improved microbial balance, enhanced SCFAs production, and reduced inflammatory signaling. Therapeutic dietary strategies demonstrate varying levels of effectiveness. The MD and the CDED stand out for their reproducible benefits on microbiota composition, inflammatory markers, and patient-reported outcomes, reinforcing their potential as complementary tools in long-term management. EEN uniquely achieves mucosal healing in pediatric CD, while modified approaches improve tolerability without compromising therapeutic effect. In contrast, the low FODMAP diet provides symptom relief for functional gastrointestinal complaints but does not attenuate intestinal inflammation, underscoring the need for careful, supervised use. Micronutrient deficiencies remain highly prevalent and clinically significant. Robust evidence supports routine assessment and targeted correction of vitamin D, vitamin B12, iron, and zinc, each of which exerts clear and quantifiable effects on immune function, anemia, bone health, and treatment responsiveness. AOs may offer additional benefits in mitigating oxidative stress, though current findings are insufficient for definitive clinical recommendations. Probiotic utility remains strain-specific, with evidence supporting only E. coli Nissle 1917 and VSL#3 for maintaining remission in UC. Overall, current knowledge supports the integration of structured nutritional assessment and evidence-based dietary interventions into standard IBD management. As diet influences microbial composition, immune pathways, and clinical outcomes, nutrition should be viewed not as complementary care but as a core therapeutic domain. Advancing the field will require rigorously designed trials and precision-nutrition approaches that incorporate individual microbiome and metabolomic profiles, enabling more targeted and effective dietary recommendations for patients with IBD.